Warfarin pharmacogenetics: Polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population

Human Biology

Volumn 84, Issue 1, 2012, Pages 67-77

  Pathare, Anil V ^a   Al Zadjali, Shoaib ^a   Misquith, Rhea ^a   Alkindi, Salam S ^a,b   Panjwani, Vinodh ^a   Lapoumeroulie, Claudine ^c   Pravin, Sahaya ^c   Paldi, Andras ^d   Krishnamoorthy, Rajagopal ^c  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b Sultan Qaboos University College of Medicine and Health Sciences   (Oman)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UMRS 951 ^*  (France)

Author keywords

CYP2C9; CYP4F2; Omani; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

EID: 84859519012     PISSN: 00187143     EISSN: 15346617     Source Type: Journal    
DOI: 10.1353/hub.2012.0002     Document Type: Article

References (23)

1. Ansell, J., J. Hirsh, E. Hylek et al. 2008. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S-198S.
2. Caldwell, M. D., T. Awad, J. A. Johnson et al. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112.
3. Cooper, G. M., J. A. Johnson, T. Y. Langaee et al. 2008. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027.
4. Daar, S., H. M. Hussain, D. Gravell et al. 2000. Genetic epidemiology of HbS in Oman: Multicentric origin for the betaS gene. Am. J. Hematol. 64:39-46.
5. D'Andrea, G., R. D'Ambrosio, P. Di Perna et al. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649.
6. Geisen, C., M. Watzka, K. Sittinger et al. 2005. VKORC1 haplotypes and their impact on inter-individual and inter-ethnic variability of oral anticoagulation. Thromb. Haemost. 94:773-779.
7. Handley, L. J., A. Manica, J. Goudet et al. 2007. Going the distance: Human population genetics in a clinal world. Trends Genet. 23:432-439.
8. Kaminsky, L. S., S. M. de Morais, M. B. Faletto et al. 1993. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol. Pharmacol. 43:234-239.
9. Limdi, N. A., M. Wadelius, L. Cavallari et al; International Warfarin Pharmacogenetics Consortium. 2010. Warfarin pharmacogenetics: VKORC1 genotype as predictive as haplotype across three racial groups. Blood 115:3827-3834.
10. Lindh, J. D., S. Lundgren, L. Holm et al. 2005. Several-fold increase in risk of over anticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78:540-550.
11. Rettie, A. E., L. C. Wienkers, F. J. Gonzalez et al. 1994. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42.
12. Rieder, M. J., A. Reiner, B. F. Gage et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352:2285-2293.
13. Schelleman, H., J. Chen, Z. Chen, J. Christie et al. 2008. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84:332-339.
14. Scott, S. A., M. Jaremko, S. A. Lubitz et al. 2009. CYP2C9*8 is prevalent among African-Americans: Implications for pharmacogenetic dosing. Pharmacogenetics 10:1243-1255.
15. Scott, S. A., R. Khasawneh, I. Peter et al. 2010. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenetics 11:781-799.
16. Sistonen, J., S. Fuselli, J. U. Palo et al. 2009. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenetics and Genomics 19:170-179.
17. Takahashi, H., T. Kashima, S. Nomoto et al. 1998. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365-373.
18. Takahashi, H., H. Echizen. 2003. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenetics J. 3:202-214.
19. Takeuchi, F., R. McGinnis, S. Bourgeois et al. 2009. A Genome-Wide Association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genetics 5:1-9.
20. Tanira, M. O., M. K. AlMukhaini, A. T. Al-Hinai et al. 2007. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genetics 10:32-37.
21. Teichert, M., M. Eijgelsheim, F. Rivadeneira et al. 2009. A genome-wide association study of acenocumarol maintenance dosage. Hum. Mol. Genet. 18:3758-3768.
22. Wang, S. L., J. Huang, M. D. Lai et al. 1995. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42.
23. Yuan, H. Y., J. J. Chen, M. T. Lee et al. 2005. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14:1745-1751.